Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

NCT01229943 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01229943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01229943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2010
Completion date
January 3, 2018
Enrollment
150 (actual)
Sites
394

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic neuroendocrine tumor, locally advanced pancreatic neuroendocrine tumor, pancreatic gastrinoma, pancreatic neuroendocrine tumor g1, pancreatic neuroendocrine tumor g2, pancreatic vipoma